- Home
- KLTOW vs GUTS Comparison
KLTOW vs GUTS Comparison
Compare KLTOW & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTOW
- GUTS
- Stock Information
- Founded
- KLTOW N/A
- GUTS 2010
- Country
- KLTOW United States
- GUTS United States
- Employees
- KLTOW N/A
- GUTS N/A
- Industry
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- GUTS
- Sector
- KLTOW Health Care
- GUTS
- Exchange
- KLTOW Nasdaq
- GUTS NYSE
- Market Cap
- KLTOW N/A
- GUTS 110.1M
- IPO Year
- KLTOW 2022
- GUTS 2024
- Fundamental
- Price
- KLTOW $0.03
- GUTS $1.79
- Analyst Decision
- KLTOW
- GUTS Buy
- Analyst Count
- KLTOW 0
- GUTS 2
- Target Price
- KLTOW N/A
- GUTS $18.00
- AVG Volume (30 Days)
- KLTOW N/A
- GUTS 299.7K
- Earning Date
- KLTOW N/A
- GUTS 02-02-2025
- Dividend Yield
- KLTOW N/A
- GUTS N/A
- EPS Growth
- KLTOW N/A
- GUTS N/A
- EPS
- KLTOW N/A
- GUTS N/A
- Revenue
- KLTOW N/A
- GUTS $97,000.00
- Revenue This Year
- KLTOW N/A
- GUTS N/A
- Revenue Next Year
- KLTOW N/A
- GUTS N/A
- P/E Ratio
- KLTOW N/A
- GUTS N/A
- Revenue Growth
- KLTOW N/A
- GUTS N/A
- 52 Week Low
- KLTOW N/A
- GUTS $1.74
- 52 Week High
- KLTOW N/A
- GUTS $14.50
- Technical
- Relative Strength Index (RSI)
- KLTOW N/A
- GUTS 36.46
- Support Level
- KLTOW N/A
- GUTS $2.00
- Resistance Level
- KLTOW N/A
- GUTS $2.13
- Average True Range (ATR)
- KLTOW 0.00
- GUTS 0.20
- MACD
- KLTOW 0.00
- GUTS -0.05
- Stochastic Oscillator
- KLTOW 0.00
- GUTS 4.76
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.